but he should have waited..... Maybe it wouldn't look good if he knew something was coming if he exercised early today... I dont know but guess we will find out
The Options outstanding can be found in the latest proxy on the PVCT website.... they exercised 1.254M options over the last 5 months.... all were exercised except dees....Maybe Dees like spending money and is 63 with 5-7 millions shares.
Gots to be something
50% paid via cash and the other 50% is a lien against the stock....Will be paid back on sale of the company or they sell stock to pay back...If you pull up the Proxies all the way back to 2002/2003 you will see all in all not over paid. In fact 2002 No salary taken...
Presentation statements about PV-10 by Moffitt Cancer Center's Dr. Vernon Sondak on Friday, June 27th at the 4th European Post-Chicago Melanoma Meeting.
1. Simple to store, handle and use and reuse
2. Modest local toxicity and minimal to no systemic toxicity
3. Rapid and complete induction of necrosis/antigen release in injected lesions
4. Excellent healing of the injected site after tumor necrosis
5. Reliable and reproducible induction of regional and systemic immune effects capable of destroying occult tumor cells, "bystander lesions" and distant metastatic lesions regardless of prior treatments
Ablation of locally recurrent melanoma
Defined as within 2 cm of the primary site
AJCC stage poorly defined
Ablation of dermal or subcutaneous regionally recurrent ("in transit") melanoma
Defined as 2 cm from the primary stite and not beyond the first regional nodal basin
Stage IIIB or IIIC depending on nodal status
Ablation of dermal or subcutaneous metastatic melanoma beyond the nodal basis
Stage IV M1a disease
Induction of necrosis/antigen release and presentation in dermal or subcutaneous metastatic melanoma in patients with multifocal stage IV disease prior to or concomitant with systemic immunotherapy
"Consolidation" by ablation of residual dermal or subcutaneous metastatic melanoma in patients with multifocal stage IV disease after treatment with systemic therapy
Elimination of resistant clones
Conversion from partial to complete response
September 2013 saying: "I think the drug has some serious potential as an immune modulator, and would be very interesting to combine with checkpoint inhibitors."
May 2014 "It also provides a rationale for combination trials of PV-10 with check point protein inhibitors, such as ipilimumab, pembrolizumab and nivolumab. PV-10 might offer the perfect way to prime the immune system”
Will at least be interesting along with PFE.
Wonder how he will try to belittle the deal.
50% of these folks can't take the drug..... sounds to me that pvct has a target market.... NTTG calls 50% salvage therapy i will take it.
If the drug was Obsolete they wouldn't have a CUP program with over a 100 patients.... I guess these patients were part of the folks that Surgery will not work and have failed Yervoy etc... I think the failure rate is 50% or so according to Weber..
Let's just get it approved for the Refractory patients and then it can be used off label...